OCT50 (CD22/Siglec-2)
Siglec-2 regulates BCR antigen response. This critical checkpoint is disrupted during autoimmune onset and flare. OCT50 restores the endogenous role of Siglec-2, selectively suppressing autoreactive B cells and resetting healthy immune functioning.
OCT102 (Undisclosed Checkpoint)
OCT102 suppresses the secretion of inflammatory cytokines, including IL-6, IL-17, and type 1 interferon, by CD8+ T cells. Cytokine secretion is directly pathogenic in a number of inflammatory diseases.
Metabolic Diseases (Partnered)
Octagon has an active discovery program targeting immune cell populations that drive inflammatory and fibrotic processes. Octagon’s platform enables the unique ability to target disease-associated lymphocytes with a high level of specificity, directly addressing the drivers of disease. This approach has formed the basis for a multi-year partnership with Novo Nordisk, a global leader in cardiometabolic disease.